APA (7th ed.) Citation

M, A., F, M., S, J., & A, A. (2026). Cost-benefit analysis of nirsevimab for respiratory syncytial virus prevention in infants: A population-based study. European journal of pediatrics, 185(7), . https://doi.org/10.1007/s00431-026-07207-8

Chicago Style (17th ed.) Citation

M, Alonso-García, Martos-Barrachina F, Jiménez-Bueno S, and Arce-Arnáez A. "Cost-benefit Analysis of Nirsevimab for Respiratory Syncytial Virus Prevention in Infants: A Population-based Study." European Journal of Pediatrics 185, no. 7 (2026). https://doi.org/10.1007/s00431-026-07207-8.

MLA (9th ed.) Citation

M, Alonso-García, et al. "Cost-benefit Analysis of Nirsevimab for Respiratory Syncytial Virus Prevention in Infants: A Population-based Study." European Journal of Pediatrics, vol. 185, no. 7, 2026, https://doi.org/10.1007/s00431-026-07207-8.